कंपनी का अवलोकन
InspireMD, Inc. is a medical device firm dedicated to the development and commercialization of specialized products designed to treat carotid artery disease and various other vascular conditions. The company operates within the broader healthcare sector, specifically focusing on the medical devices industry, which implies a reliance on regulatory approvals, technological innovation, and clinical efficacy for its products. Its operational footprint extends beyond the United States to include markets in Germany, Italy, Russia, Poland, and other international regions. As of the latest data, InspireMD, Inc. holds a market capitalization of $65.05M, generates $8.98M in annual revenue, and employs 127 staff members. These valuation and revenue figures indicate that InspireMD, Inc. is a mid-sized micro-cap entity, suggesting a company that is still in a phase of scaling operations and establishing its market presence rather than a mature, cash-flow-positive giant. The relatively modest market cap alongside significant revenue growth highlights a potential for expansion, though the small employee base underscores the early-stage nature of its commercialization efforts.
वित्तीय स्वास्थ्य
The company reported trailing twelve-month revenue of $8.98M, yet it recorded a net income of $-48,786,000 and an EBITDA of $-49,138,000. The substantial negative gap between revenue and net income reveals a highly aggressive cost structure or significant one-time expenses that are not fully covered by current sales, indicating that revenue alone is insufficient to cover total operational outlays. Free cash flow stands at $-18,728,750, which signifies that the company is burning cash through its operations and investments, thereby limiting its immediate financial flexibility and necessitating reliance on existing cash reserves or external financing. Margin analysis shows a gross margin of 29.5%, suggesting that the cost of goods sold consumes roughly 70.5% of revenue, while the operating margin is a severe negative 383.7% and profit margin is 0.0%, indicating that operating expenses are vastly exceeding gross profits and the company is currently unprofitable on an accrual basis. Regarding liquidity and leverage, InspireMD, Inc. holds $54.21M in cash against $3.29M in debt, supported by a current ratio of 5.74, which indicates a very strong short-term liquidity position capable of covering current liabilities more than five times over. However, the debt-to-equity ratio of 5.96 suggests a leveraged balance sheet structure where debt obligations are high relative to shareholder equity, creating a potential risk if cash flows do not improve rapidly. Furthermore, the return on equity is -106.9% and return on assets is -53.4%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently due to the persistent lack of profitability.
मूल्यांकन आकलन
Valuation metrics present a complex picture for InspireMD, Inc., with a trailing P/E ratio listed as N/A and a forward P/E of -2.29. The existence of a negative forward P/E implies that the market expects earnings to remain negative or that the current earnings trajectory is so poor that a traditional multiple cannot be applied, reflecting high uncertainty regarding future profitability. The price-to-book ratio is 1.10, which indicates that the stock trades at a slight premium of 10% over its book value, suggesting investors are willing to pay slightly more than the net asset value despite the company's losses. Alternative valuation measures include a price-to-sales ratio of 7.25 and an EV/EBITDA of -0.29, suggesting that the market is pricing the company based on revenue multiple rather than earnings power, a common approach for pre-profitable biotech or medical device firms. In terms of trading range, the 52-week high is $2.93 and the low is $1.39; assuming the current price sits near the lower end of the spectrum given the negative earnings, the stock is trading significantly below its yearly peak, reflecting the market's caution regarding its financial performance. The beta value is 0.94, which means the stock's price volatility is nearly identical to that of the broader market, indicating it does not offer significant downside protection nor substantial upside leverage compared to the S&P 500.
Growth & Income
InspireMD, Inc. demonstrates robust top-line expansion with a revenue growth rate of 61.6% year-over-year, while earnings growth is N/A due to the company's current unprofitable status. The absence of earnings growth relative to revenue is expected given the net loss position, implying that the company is prioritizing market share capture and product development over immediate profit generation. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, which confirms that all available cash is being reinvested into growth initiatives, R&D, and working capital rather than distributed to shareholders. This reinvestment strategy is typical for companies in the development or early commercialization phases of medical device innovation. The overall growth and income profile is characterized by high revenue acceleration but a complete lack of distributable income or earnings growth, positioning InspireMD, Inc. as a pure-play growth investment with significant capital deployment risks. The combination of high revenue growth and negative earnings suggests a high-risk, high-reward scenario dependent on the successful commercialization of its vascular disease treatment products.